Improving Hemophilia A Care and Patient Adherence: Planning Prophylaxis to Meet Individual Patients’ Needs
Presentation Points Presentation Points

Improving Hemophilia A Care and Patient Adherence: Planning Prophylaxis to Meet Individual Patients’ Needs


Released:
12/5/19
Expires:
12/4/20

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Presentation Points Presentation Points
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
12/5/19

Expires:
12/4/20

Maximum Credits:
0.5
Presentation Points Presentation Points
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
12/5/19
Expires:
12/4/20


Maximum Credits:
0.5


Overview: This 30-minute, accredited Presentation Points publication highlights key evidence and clinical pearls from live workshops delivered by expert faculty at federally funded hemophilia treatment centers (HTCs). Focusing on the evolving paradigm for prophylaxis and the management of patients with hemophilia A, this transcript-based publication provides expert insight on the role of extended half-life factor VIII and nonfactor replacement therapy in prophylaxis and strategies for engaging patients in shared decision making to help navigate increasingly complex treatment choices and improve patient adherence.

CME Information:

Faculty
Courtney Thornburg, MD, MS

Professor of Clinical Pediatrics
Division of Hematology-Oncology
UC San Diego School of Medicine
Medical Director, Hemophilia and Thrombosis Treatment Center
Rady Children’s Hospital San Diego
San Diego, CA

Guy Young, MD
Professor of Pediatrics
Division of Hematology, Oncology and Bone Marrow Transplantation
USC Keck School of Medicine
Director, Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles
Los Angeles, CA

Activity Planners
Erin Mooney, MS
Clinical Content Manager
Med-IQ
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Outline clinical evidence on the risks and benefits of available prophylactic strategies in the individualized management of hemophilia A
  • Apply core principles of shared decision making to engage patients with hemophilia A and/or their caregivers

Target Audience
This activity is intended for hematologists, pediatric hematologists, and nurses specializing in hematology.
 
Statement of Need
Recent treatment advances have transformed the care of hemophilia A, a congenital, X-linked bleeding disorder caused by coagulation factor VIII deficiency. However, only 60% of adults with this condition are adherent to prophylactic therapy, and patient-reported adherence in adolescents can be as low as 30%. The prophylaxis schedule associated with factor VIII replacement therapy is burdensome to patients due to its short half-life, but extended half-life agents that require fewer injections per week help reduce this burden. However, these agents are recombinant factor VIII and carry a higher risk of patients developing inhibitors. Fortunately, several novel therapeutic approaches have entered the market that either mimic factor VIII or reduce the function of anticoagulants. These advances in therapy have provided the opportunity for hematologists to individualize the prophylactic treatment of hemophilia A but have also increased the complexity of treatment decision making. In light of the expanding hemophilia A treatment landscape and ongoing challenges to treatment adherence, incorporating patient preferences into the decision-making process is central to improving outcomes. Strategies for shared decision making provide an excellent approach for clinicians to deliver relevant and interpretable information to patients and receive well-considered patient preferences. The use of shared decision making and inclusion of newer agents in prophylaxis treatment strategies for appropriate patients will help improve adherence to therapy and long-term hemophilia A–related outcomes..
 
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statement
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This nursing activity has been approved for up to 0.5 contact hour.

Medium/Method of Participation
This CME/CE activity consists of a 0.5-credit presentation points. To receive credit, read the introductory CME/CE material, read the presentation points, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: December 5, 2019
Expiration Date: December 4, 2020
Estimated Time to Complete This Activity: 30 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Courtney Thornburg, MD, MS
Consulting fees/advisory boards: Bioverativ, Bluebird Bio, Ironwood Pharmaceuticals, Inc., Spark Therapeutics
Fees received for promotional/non-CME activities: Genentech
Contracted research: Bayer HealthCare Pharmaceuticals, Novo Nordisk, Octapharma, Sanofi Genzyme

Guy Young, MD
Consulting fees/advisory boards: CSL Behring, F. Hoffman-La Roche Ltd., Genentech, Grifols, Kedrion, Novo Nordisk, Spark Therapeutics, Takeda Pharmaceuticals North America, Inc., uniQure
Fees received for promotional/non-CME activities: Bioverativ, CSL Behring, F. Hoffman-La Roche Ltd., Grifols, Novo Nordisk, Sanofi Genzyme, Spark Therapeutics, uniQure
Contracted research: Genentech

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.

Copyright
© 2019 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.